Randomized, double blind, placebo controlled trial
June 4, 2020
110,190
3,256
1,764
4.56%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around June 4, 2020
See what was published immediately before and after this episode.
28:50Now PlayingRandomized, double blind, placebo controlled trial
YouTube Description
as posted by the channelA Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 (3rd June)
BACKGROUND
Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.
METHODS
Randomized, double-blind, placebo-controlled trial
United States and Canada
Testing hydroxychloroquine as postexposure prophylaxis
High risk, less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield
Moderate risk, while wearing a face mask but no eye shield
n = 821 asymptomatic participants (719 of 821) reported a high-risk exposure
Randomly assigned, placebo or hydroxychloroquine groups within 4 days of exposure
Primary outcome, incidence positive test of clinical diagnosis
RESULTS
Incidence of new illness
Hydroxychloroquine group (49 of 414), 11.8%
Placebo group (58 of 407), 14.3%
P=0.35
Side effects in hydroxychloroquine group = 40.1%
Side effects in control group = 16.8%
No serious adverse reactions were reported.
(Nausea, upset stomach, dizziness, headache)
Hydroxychloroquine group
Taking zinc 15% developed new disease
Not taking zinc 10.8% developed new disease
Placebo group
Taking zinc 15.4% developed new disease
Not taking zinc 14% developed new disease
Relative risk with zinc use was 1.23
Hydroxychloroquine group
Taking Vit C 14.3% developed new disease
Not taking Vit C 10.6% developed new disease
Placebo group
Taking Vit C 20.8% developed new disease
Not taking Vit C 11.2% developed new disease
Relative risk with vitamin C use was 1.60
The Lancet (and NEJM)
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, (May 22nd)
Serious scientific questions about the validity of data
‘Expression of Concern’
)312903/fulltext
Issued a correction regarding location of some patients
Conclusions were not changed.
WHO resumed its trial of hydroxychloroquine
Crisis of trust
Medical journals
WHO
Governments
Scientific / medical advisors
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.